A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting.

Condition:   Metastatic Breast Cancer Intervention:   Drug: Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen) Sponsors:   German Breast Group;   Pfizer;   Advanced Medical Services;   Philips Respironics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials